Physician profile
Audra M Jackson
NPI 1093815268
$1,274.80
in general payments reported to CMS, 2019-2025
25 companies · $93.73 in 2025
The $93.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $29.77 · 2021: $130 · 2022: $238 · 2023: $134 · 2024: $96.65 · 2025: $93.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $345.39 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $110.24 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $83.91 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $77.38 | 2019-2022 | |
| Abbott Laboratories | $76.24 | 2022-2024 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.57 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $58.30 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Avanir Pharmaceuticals, INC. | $55.88 | 2019 | |
| Exact Sciences Corporation | $33.26 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $31.90 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $24.56 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.24 | 2019 | |
| Alkermes, INC. | $19.89 | 2022 | |
| Sanofi Pasteur INC. | $19.09 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.52 | 2025 | |
| Amneal Pharmaceuticals LLC | $17.77 | 2019 | |
| Astellas Pharma US INC | $17.03 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.82 | 2021 | |
| Lundbeck LLC | $15.85 | 2019 | |
| Genzyme Corporation | $15.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.55 | 2021 | |
| Allergan, INC. | $14.03 | 2020 | |
| Currax Pharmaceuticals LLC | $13.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.